德银质疑阿斯利康(AZN.US)关键乳腺癌药物前景 罕见给予“卖出”评级

Core Viewpoint - Deutsche Bank analyst Emmanuel Papadakis has downgraded AstraZeneca (AZN.US) to a "sell" rating, expressing a more cautious outlook on the company's drug development pipeline, particularly its breast cancer therapy [1] Summary by Category Analyst Ratings - The stock rating for AstraZeneca has been lowered from "hold" to "sell," with a target price reduced to £105, representing a potential downside of 16% from recent highs [1] Drug Development Pipeline - The analyst believes that AstraZeneca's key breast cancer drug, camizestrant, is unlikely to demonstrate significantly better efficacy compared to competing drugs [1] - There is an increasing pressure from patent expirations, suggesting that the current valuation may be too high [1] Market Sentiment - Despite the downgrade, approximately three-quarters of other analysts remain optimistic, giving "buy" recommendations, with an average 12-month target price exceeding £140 [1]